Jun 26, 2015 · Celladon ($CLDN) is circling the drain, suspending all research tied to its failed gene therapy and again halving its payroll as management searches for a sale and flirts with liquidation.

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure.

Celladon has raised $116M. Who are Celladon’s investors? Domain Associates , EQT Life Sciences , EcoR1 Capital , Enterprise Partners Venture Capital , and GBS Venture Partners are 5 of 15 investors who have invested in Celladon.

The universe of data and correspondence innovation has increased its significance with the developing number of clients, becoming fundamental both for people and for the activity of organizations and organizations.

LUNCH 11a - 3p. DINNER 4:30p - 9:30p or 10p. PHONE 518.250.5551. ADDRESS 860 New Loudon Rd. Latham, NY

Apr 26, 2015 · A year ago, the FDA handed out "breakthrough" status for Celladon's Mydicar, a gene therapy designed to insert a functioning copy of the SERCA2a gene into heart cells in an effort to salvage ...

Jun 26, 2015 · WIKIMEDIA, NATIONAL INSTITUTES OF HEALTH Following an announcement in April that its gene therapy product does not work, the San Diego-based biotech Celladon is halving its staff and suspending research and development operations.

Gene therapy for heart failure hit another bump on the road to clinical translation with the announcement by Celladon that its lead product Mydicar—adeno-associated viral vector 1 (AAV1)-expressing sarcoplasmic reticulum calcium ATPase (SERCA2a)—had failed in the phase IIb CUPID2 trial. 1 SERCA2a's role in heart failure was validated in the ...

Apr 14, 2014 · Clinical-stage biotechnology firm Celladon has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its lead product candidate, Mydicar, for reducing hospitalisations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative.

Apr 12, 2014 · Celladon Corporation, a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for ...